Clostridium difficile infection in an Iranian hospital by Jalali, Mohammad et al.
SHORT REPORT Open Access
Clostridium difficile infection in an Iranian hospital
Mohammad Jalali
1, Farzin Khorvash
2, Keith Warriner
3 and J Scott Weese
4*
Abstract
Background: Clostridium difficile infection (CDI) is an important cause of morbidity and mortality internationally, yet
there are important regional differences in the epidemiology and microbiology of disease. Most reports have come
from North America and Europe, with limited information from other regions, including the Middle East. Given the
changes in the epidemiology of CDI in developed countries, particularly associated with the dissemination of
hypervirulent epidemic clones, an understanding of the epidemiology and microbiology of CDI in diverse regions is
warranted. This study involved collection of stool samples from individuals with diarrhea at the Isfahan University of
Medical Sciences Teaching Hospital, Isfahan, Iran, between October 2010 and March 2011. Selective enrichment
culture for C. difficile was performed and isolates were characterised using ribotyping, PCR for the detection of tcdA,
tcdB and cdtB genes, and tcdC sequence analysis.
Findings: Clostridium difficile was isolated from 19/89 (21%) stool samples of 17/86 (20%) patients. 13/17 (77%) cases
of CDI were hospital-associated. Patients with CDI were significantly older (43 ± 28y) than those with non-CDI
diarrhea (24, ± 26y)(P = 0.018). All isolates were toxigenic, and possessed genes encoding for toxins A and B. Six
(32%) of 19 isolates also possessed cdtB. Twelve ribotypes were identified. Ribotype 078/toxinotype V was most
common, accounting for 4 (21%) of isolates. A single isolate of a different toxinotype V ribotype was identified, as
was a toxinotype XXIV isolate. The remaining isolates consisted of 9 different toxinotype 0 ribotypes.
Conclusions: CDI is an important cause of diarrhea in patients in this hospital. The diversity of ribotypes was
striking, and the number of different types suggests the presence of a broad range of strains in the community, the
hospital or both. The predominance of toxinotype V strains, which have been associated with community-
associated disease and food animals, was unexpected and possible sources of this type require further investigation.
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Findings
Clostridium difficile is a leading cause of hospital-asso-
ciated and antimicrobial-associated diarhea, and is of sig-
nificant concern because of the increasing morbidity,
mortality and relapse rates [1], along with the emergence
of community-associated disease [2]. Some of these clin-
ical and epidemiological changes have been associated
with dissemination of hypervirulent clones, particularly
ribotype 027 (toxinotype III, North American pulsotype
(NAP)1)[3] and to a lesser degree ribotype 078 (toxino-
type V, NAP7/8) [4,5]. Clostridium difficile infection
(CDI) has been reported throughout much of the world,
but most data come from developed countries in North
America and Europe. Limited information is available
regarding the role of C. difficile in diarrheic hospital
patients in people in Iran or other Middle Eastern coun-
tries, or about C. difficile strains that are involved.
Therefore, the aim of present study was to determine the
prevalence of C. difficile in diarrheic patients in hospital
in Isfahan, Iran, and to characterize isolates.
The study was conducted at the Isfahan University of
Medical Sciences Teaching Hospital, Isfahan, Iran, the
largest tertiary care medical centre in the region with
800 beds, three intensive care units and all major clinical
specialties. Aliquots of stool specimens that had been
collected from diarrheic patients between October 2010
and March 2011 for other diagnostic testing were stud-
ied. Both patients that were admitted to hospital with
diarrhea and those who developed diarrhea during
hospitalization were included. Diarrhea was defined as
watery, loose or unformed stool passed at a frequency of
three times or more per 24 hours. Demographic and
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ical record. Cases were classified as community associated
(CA) if the onset of symptoms occurred prior to, or within
48 h of admission and if they had not been hospitalized in
the preceding 3 months [6]. Cases were classified has hos-
pital-associated (HA) if the onset was greater than 48 h
after admission. Cases that had diarrhea at admission or
developed diarrhea within the first 48 h of admission but
had been hospitalized within the preceding 4 weeks were
classified as hospital-associated, community-onset (HA-
CO). Studies such as this are exempt from ethics board
review at Isfahan University and instead require approval
of the Isfahan University of Medical Sciences Vice Chan-
cellor for Research, which was obtained.
Selective enrichment culture was performed. Approxi-
mately 5 g of stool was inoculated into 25 ml of C. difficile
selective enrichment broth containing 40 g/l proteose pep-
tone, 5.0 g/l disodium hydrogen phosphate, 0.1 g/l magne-
sium sulphate, 2.0 g/l sodium chloride, 6.0 g/l fructose and
1.0 g/l sodium taurocholate supplemented with cysteine
hydrochloride, norfloxacin and moxalactam, and anaer-
obically incubated at 37 C for 5–7 days. Two ml of each
culture were then added to an equal volume of absolute
ethanol, mixed and left at room temperature for 1 h. Alco-
hol shocked cultures were then centrifuged (4000 rpm/
10 min) and the pellet was streaked onto C. difficile moxa-
lactam norfloxacin (CDMN) agar (Oxoid) and incubated
anaerobically at 37 C for 24-48 h. Suspect colonies were
subcultured and identified as C. difficile on the basis of
characteristic colony morphology, odour, Gram stain
morphology and L-proline aminopeptidase test (Prodisk,
Remeb, Lenexa, KS, USA). All isolates were screened for
the presence of genes encoding toxin A (tcdA), toxinB
(tcdB), the binding component of CDT (cdtB)a n dt r i o s e
phosphate isomerase (tpi) as have been previously
described [7-9]. Isolates were also subjected to PCR ribo-
typing [10], toxinotyping[11] and tcdC sequence analysis
[12]. For ribotyping, ribotypes were assessed visually and
compared to an internal collection of ribotypes from
over 3000 isolates from humans and animals. When a
ribotype pattern was known to be a recognized inter-
national ribotype through previous typing of reference
strains from the HPA Anaerobic Reference Laboratory
(http://www.webcitation.org/64HSI8B56) (Cardiff, UK),
the appropriate numerical designation (i.e. 078) was
used. Otherwise, internal nomenclature was used.
Categorical comparisons were performed using Fisher’s
exact test while t-test was used for continuous data. A P
value of <0.05 was considered significant.
Eighty-six diarrheic patients were enrolled. Clostridium
difficile was isolated from 19/89 (21%) of stool samples
from 17/86 (20%) patients; 8/36 (22%) women and 9/50
(18%) men (P=0.78). 13/17 (76%) cases were HA-CDI
while the other 4 (24%) were CA-CDI. Patients with CDI
were significantly older (43±28y) than those with non-
CDI diarrhea (24, ± 26y)(P=0.018). Five (29%) CDI
patients were over the age of 65 compared to 6/69 (8.7%)
without non-CDI diarrhea (P=0.037). Fifteen (88%) of
CDI patients had received antimicrobials prior to the
onset of diarrhea, compared to 58 (84%) others (P=1.0).
Two patients had separate episodes of diarrhea 62 and
33 days apart, and the same ribotype was isolated from
each episode. Follow-up data were limited but this repre-
sents a minimal recurrence rate of 12%. Two (12%)
patients with CDI died during hospitalization, however
death was only attributed to CDI in 1 (5.9%) individual.
All isolates possessed genes encoding for toxins A and
B, and 12 different ribotypes were identified (Table 1).
In addition to tcdA and tcdB, six (32%) isolates also pos-
sessed cdtB. Four of these were ribotype 078 and toxino-
type V, and contained a 39 bp deletion and C184T
nonsense mutation in tcdC. One ribotype was a toxino-
type V isolate that differed from ribotype 078 but had
the same tcdC deletion and mutation. Patients carrying
these five isolates were admitted over a period of ap-
proximately 2 months, with no more than one per week
(Figure 1). The other cdtB positive isolate was a toxino-
type XXIV strain that contained an 18-bp tcdC deletion
in tcdC but not the upstream truncating mutation that
is characteristic of the toxinotype III hypervirulent ribo-
type 027/NAP1. The remaining 13 isolates from 11
patients were toxinotype 0 strains consisting of 9 differ-
ent ribotypes, including ribotype 014 and 8 ribotypes
not previously encountered in this laboratory.
All 4 patients from which ribotype 078 was isolated
were from rural areas, but had hospital-associated diar-
rhea. The mean age of patients with ribotype 078 was
29.2y compared to 49.1y for other ribotypes, but this was
not statistically significant (P=0.25)
Table 1 Ribotype and toxinotype data for Clostridium
difficile isolated from diarrheic individuals in an Iranian
hospital
Ribotype n Toxin gene profile Toxinotype
078 4 tcdA, tcdB, cdtB V
IR1 1 tcdA, tcdB, cdtB V
014 1 tcdA, tcdB 0
IR2 1 tcdA, tcdB, cdtB XXIV
IR3 1 tcdA, tcdB 0
IR4 3 tcdA, tcdB 0
IR5 1 tcdA, tcdB 0
IR6 1 tcdA, tcdB 0
IR7 1 tcdA, tcdB 0
IR8 1 tcdA, tcdB 0
IR9 1 tcdA, tcdB 0
IR10 1 tcdA, tcdB 0
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studies of hospitalized individuals in other regions, albeit
higher than two recent Iranian studies that reported iso-
lation of toxigenic C. difficile from 6.1-6.8% of stool sam-
ples [13,14]. Other regional studies have reported 4.6-
9.5% prevalence in two studies from Saudi Arabia [15],
10.5% in Kuwait [16], and 13.7% from Jordan [17].
However, limited emphasis should be placed on com-
parisons of prevalence because of differences in study
methodology. The key finding is that CDI appears to be
common in patients in Iranian hospitals, and may be
underdiagnosed since testing appears to be rarely per-
formed, in part because of limited access to commercial
assays.
As is consistent with other reports, CDI was associated
with older individuals. However, in this study, the CDI
patients were younger (mean 43y) compared to most
other reports [1,18] and less than 30% of CDI patients
were over the age of 65. Reasons for this difference are
not apparent. Classically, CDI has been considered a dis-
ease predominantly of elderly individuals, however there
are increasing reports of CDI in younger individual, in-
cluding people that would be considered at low risk of
infection [19-21]. Only limited investigation of risk fac-
tors was performed here based on the available data.
There was no association between antimicrobial use and
CDI in these patients, however antimicrobial use was
very common in both CDI and non-CDI groups, and the
role of antimicrobials in CDI can certainly not be dis-
missed by these data.
Community-associated CDI is being more commonly
reported in some regions, often associated with milder
disease in younger individuals and people with little or
no antimicrobial exposure [2,20,22]. In this study, 23% of
cases were classified as CA-CDI, and all involved
different toxinotype 0 strains. While the majority of cases
were therefore associated with hospitalization, it cannot
be stated with certainty that exposure occurred in hos-
pital since testing of patients at admission, prior to the
onset of disease, would be required to ensure that they
were not carrying C. difficile at the time of admission.
Since there was a wide diversity in types and little evi-
dence of temporal clustering (Figure 1), a point-source of
hospital exposure was not apparent. Hospital-associated
CDI could have occurred from exposure of different
patients to different strains in hospital, but also could
have been the result of development of disease from C.
difficile that was resident in the intestinal tract at the
time of admission.
The wide diversity of ribotypes was interesting. Toxi-
notype 0 strains predominated, yet only 1 isolate (ribo-
type 014) was consistent with major reported human
types. The diversity of ribotypes within toxinotype 0
strains and the differences between common toxinotype
0 ribotypes in this versus other studies was interesting.
The relatively high prevalence of ribotype 078 was con-
sistent with two studies from Kuwait that identified ribo-
type 078 as one of the predominant types [23,24].
Additionally, the one other toxinotype V isolate is likely
closely related to ribotype 078, and the overall prevalence
of toxinotype V strains was 29%. Recent studies have
reported increases in the prevalence of ribotype 078 or
toxinotype V strains in humans, particularly in commu-
nity-associated disease [19,25]. This strain can also be
found commonly in food animals and food [26-28], lead-
ing to concern that it might be foodborne or zoonotic
[29]. While all patients with ribotype 078 were from
rural regions, disease onset was in hospital and the ori-
gin of infection cannot be discerned. Further, no infor-
mation about animal or food contact is available, and no
Figure 1 Temporal distribution of Clostridium difficile infection caused by toxinotype V (TT V) and non toxinotype V (Non TT V) isolates.
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able for this region. Therefore no assumptions can be
made regarding potential sources of this strain. The four
patients with ribotype 078 were admitted over a 37 day
period (Figure 1), and the potential that these represent
a small hospital-associated cluster cannot be dismissed.
Ribotype 027, a toxinotype III strain associated with
hypervirulent disease and epidemics internationally [30],
was not identified in any patient. The diversity in ribo-
types is consistent with the only available Iranian study,
which reported 28 different ribotypes amongst 178 iso-
lates [14]. That study did not compare strains to inter-
nationally recognized reference strains and did not
perform other typing methods, so detailed comparison
with these data is impossible.
This study indicates that C. difficile might be an im-
portant enteric pathogen in patients in Iranian hospitals.
Efforts must be undertaken to diagnose CDI to allow for
targeted therapy and to provide a better understanding
of this important disease. While some aspects identified
here are consistent with reports of CDI in other areas,
further study of the epidemiology and microbiology of
CDI in this region is required to explore some apparent
differences, such as the younger age distribution and the
predominance of ribotype 078. While ribotype 027 was
not identified, further surveillance is required to deter-
mine whether this strain is indeed present in the country
and to monitor for its emergence.
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